Document is current

Any future updates will be listed below

The first real-world evidence on dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin followed by switch maintenance avelumab in advanced urothelial carcinoma: a propensity score-matched study

Crossref DOI link: https://doi.org/10.1007/s10147-025-02729-x

Published Online: 2025-03-03

Published Print: 2025-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark